AAPL 171.29 -4.1305% MSFT 429.37 0.9736% GOOG 148.74 -0.628% GOOGL 147.6 -0.7664% AMZN 178.15 0.0% NVDA 914.35 1.1762% META 507.76 0.4431% TSLA 172.82 -1.6168% TSM 139.45 1.9744% LLY 770.26 -0.3364% V 290.37 0.3768% AVGO 1348.0 5.6426% JPM 199.06 1.3905% UNH 491.69 -0.5139% NVO 129.83 -0.4066% WMT 61.45 0.3265% LVMUY 182.95 -1.8193% XOM 113.49 0.4425% LVMHF 913.224 -2.0146% MA 488.64 0.1229%
Last update at 2024-03-21T20:09:00Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 248.92M | 248.52M | 129.30M | -72.25100M | -79.79300M |
Minority interest | - | - | - | - | - |
Net income | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
Selling general administrative | 143.53M | 50.32M | 45.74M | 77.25M | 60.80M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 520.81M | 361.90M | 224.23M | 150.45M | 141.73M |
Reconciled depreciation | 49.64M | 3.00M | 3.28M | 4.07M | 2.39M |
Ebit | 267.53M | 272.90M | 140.97M | -71.67800M | -71.71800M |
Ebitda | 310.68M | 275.90M | 144.25M | -67.61000M | -69.33000M |
Depreciation and amortization | 43.15M | 3.00M | 3.28M | 4.07M | 2.39M |
Non operating income net other | -1.66600M | -19.85800M | 5.42M | 6.99M | 7.58M |
Operating income | 267.53M | 275.90M | 144.25M | -67.61000M | -69.33000M |
Other operating expenses | 392.58M | 167.41M | 123.34M | 263.60M | 221.19M |
Interest expense | 16.95M | 7.53M | 20.38M | 11.63M | 18.04M |
Tax provision | 46.79M | -154.19200M | 0.22M | -0.01100M | 0.54M |
Interest income | - | - | - | 4.64M | 10.46M |
Net interest income | -16.94700M | -7.52600M | -20.37800M | -11.62700M | -18.04100M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 46.79M | -154.19200M | 0.22M | -0.01100M | 0.54M |
Total revenue | 660.12M | 443.31M | 267.59M | 195.99M | 151.86M |
Total operating expenses | 253.28M | 86.00M | 79.97M | 218.06M | 211.06M |
Cost of revenue | 139.30M | 81.41M | 43.37M | 45.55M | 10.14M |
Total other income expense net | -18.61300M | -27.38400M | -14.95300M | -4.64100M | 7.58M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
Net income applicable to common shares | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 1841.51M | 1104.43M | 579.92M | 565.87M | 440.25M |
Intangible assets | 546.65M | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 45.02M | 40.48M | 28.27M | 33.37M | 20.69M |
Total liab | 1671.71M | 907.48M | 428.88M | 474.11M | 191.36M |
Total stockholder equity | 169.80M | 196.95M | 151.05M | 91.77M | 248.89M |
Deferred long term liab | - | - | - | 2.49M | 5.01M |
Other current liab | 96.52M | 24.44M | 20.48M | 55.65M | 49.53M |
Common stock | 0.14M | 0.14M | 0.14M | 0.14M | 0.14M |
Capital stock | 0.14M | 0.14M | 0.14M | 0.14M | 0.14M |
Retained earnings | 143.22M | -58.91200M | -474.59300M | -603.67800M | -531.43800M |
Other liab | 17.73M | 3.07M | 7.49M | 2.31M | 7.13M |
Good will | 409.05M | - | - | - | - |
Other assets | 71.23M | 169.35M | 14.57M | 11.58M | 4.93M |
Cash | 234.19M | 118.72M | 147.70M | 120.18M | 57.94M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 130.79M | 117.15M | 421.38M | 85.64M | 149.36M |
Current deferred revenue | 3.25M | 1.75M | 1.75M | 4.01M | 4.25M |
Net debt | 1271.90M | 757.96M | 249.53M | 282.41M | 68.44M |
Short term debt | 13.33M | 89.42M | 397.23M | 19.54M | 91.51M |
Short long term debt | 13.33M | 89.42M | 397.23M | 19.54M | 91.51M |
Short long term debt total | 1506.10M | 876.67M | 397.23M | 402.59M | 126.38M |
Other stockholder equity | 27.37M | 256.35M | 625.48M | 695.07M | 780.46M |
Property plant equipment | 75.57M | 8.79M | 10.59M | 10.86M | 7.46M |
Total current assets | 739.01M | 926.29M | 554.76M | 543.44M | 427.85M |
Long term investments | - | - | - | - | - |
Net tangible assets | -783.65000M | 196.95M | 155.07M | 90.52M | 248.89M |
Short term investments | 128.60M | 622.20M | 220.31M | 301.08M | 296.59M |
Net receivables | 231.07M | 90.97M | 97.73M | 59.44M | 30.00M |
Long term debt | 1492.77M | 787.25M | - | 383.05M | 34.87M |
Inventory | 100.12M | 53.91M | 60.75M | 29.36M | 22.62M |
Accounts payable | 17.69M | 1.54M | 1.93M | 6.43M | 4.08M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -0.92200M | -0.62000M | 0.02M | 0.24M | -0.27700M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | 0.14M | 0.14M | 0.14M | 0.14M | 0.14M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | 143.22M | -58.91200M | -474.59300M | -603.67800M | -531.43800M |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 26.80M | 13.91M | 14.57M | 11.58M | 4.93M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 1102.50M | 178.14M | 25.16M | 22.44M | 12.40M |
Capital lease obligations | - | - | - | - | - |
Long term debt total | 1492.77M | 787.25M | - | 383.05M | 34.87M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | 490.92M | -404.83200M | 79.78M | -1.50900M | 7.16M |
Change to liabilities | 24.54M | 1.17M | -36.57600M | 4.64M | 8.70M |
Total cashflows from investing activities | -487.00500M | -406.28900M | 78.35M | -5.54900M | 2.49M |
Net borrowings | 617.44M | 415.81M | -19.56000M | 338.99M | -77.51600M |
Total cash from financing activities | 362.37M | 77.86M | -106.28400M | 153.22M | -63.79700M |
Change to operating activities | -9.06400M | -11.55500M | 2.52M | -19.00600M | -5.69500M |
Net income | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
Change in cash | 115.48M | -28.98400M | 27.52M | 62.24M | -110.80400M |
Begin period cash flow | 119.22M | 148.20M | 120.68M | 58.44M | 169.24M |
End period cash flow | 234.69M | 119.22M | 148.20M | 120.68M | 58.44M |
Total cash from operating activities | 240.11M | 299.44M | 55.45M | -85.42300M | -49.50000M |
Issuance of capital stock | - | - | - | 0.00000M | 0.00000M |
Depreciation | 49.64M | 3.00M | 3.28M | 4.07M | 2.39M |
Other cashflows from investing activities | -973.11400M | - | 1.08M | -1.50900M | 7.16M |
Dividends paid | - | -12.53600M | -63.39300M | -14.22400M | - |
Change to inventory | -17.48100M | 7.37M | -31.38800M | -6.73400M | -17.48000M |
Change to account receivables | -83.94100M | 6.75M | -38.28800M | -29.43700M | 11.61M |
Sale purchase of stock | -200.00200M | -350.05800M | -150.11700M | -199.99800M | 13.72M |
Other cashflows from financing activities | 995.78M | 796.99M | 63.39M | 461.30M | 2.49M |
Change to netincome | 67.02M | -113.64700M | 16.42M | 36.14M | 35.69M |
Capital expenditures | 4.81M | 1.46M | 2.50M | 4.04M | 4.66M |
Change receivables | -83.94100M | 6.75M | -38.28800M | -29.43700M | 11.61M |
Cash flows other operating | -10.73400M | -13.80200M | -2.05700M | -17.87900M | -5.69500M |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | 115.48M | -28.98400M | 27.52M | 62.24M | -110.80400M |
Change in working capital | -85.95100M | 3.74M | -108.36600M | -50.53900M | -5.86600M |
Stock based compensation | 24.40M | 20.82M | 17.20M | 34.78M | 35.70M |
Other non cash items | 9.89M | 24.61M | 13.60M | -1.97800M | 1.70M |
Free cash flow | 235.30M | 297.98M | 52.95M | -89.46300M | -54.16300M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
HALO Halozyme Therapeutics Inc |
-0.16 0.40% | 40.22 | 20.75 | 9.49 | 6.57 | 20.57 | 7.94 | 15.81 |
NVO Novo Nordisk A/S |
-0.53 0.41% | 129.83 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
-1.53 1.17% | 129.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
3.60 0.87% | 415.71 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
CSLLY CSL Ltd |
-1.31 1.42% | 90.68 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
11388 Sorrento Valley Road, San Diego, CA, United States, 92121
Name | Title | Year Born |
---|---|---|
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | Pres, CEO & Director | 1963 |
Dr. Michael J. LaBarre Ph.D. | Chief Technical Officer | 1964 |
Ms. Nicole LaBrosse | CFO & Director | 1983 |
Ms. Tram Bui | VP of Investor Relations & Corp. Communications | NA |
Mr. Mark Snyder Esq. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. | NA |
Ms. Amy Marinne Fox | Chief HR Officer | NA |
Dr. Steve Knowles MBBS | Chief Medical Officer | NA |
Mr. Todd Butler | Chief of Staff to the CEO, VP & Head of Project Management | NA |
Dr. Christopher Bryant Ph.D. | Chief Manufacturing Officer & Head of Technical Operations | 1961 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).